Please login to the form below

Not currently logged in
Email:
Password:

GSK's Q3 sales grow 3 per cent

GlaxoSmithKline recorded a growth in sales of 3 per cent in its financial results for the third quarter of 2011, as net income remained level

GlaxoSmithKline (GSK) has recorded a growth in sales of 3 per cent in its financial results for the third quarter of 2011.

The UK-based pharmaceutical company had a turnover of $7.10bn for the period compared to $6.81bn in 2010.

Net profit for GSK remained stationery at $1.49bn, however, as costs related to selling and administration rose.

Vaccines were a particularly strong area of growth for GSK, with revenue in the division increasing by 21 per cent. This was mainly related to sales of Cervarix as part of Japan's national HPV programme.

Total turnover grew 34 per cent in Japan during the quarter, with the strong performance of Avodart following its recent launch also contributing to strong sales in the region.

Emerging markets also saw increased revenue, growing by 11 per cent, helping the company overcome a drop in sales of 5 per cent in Europe and 1 per cent in the US.

26th October 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Say Communications

Clarity of vision, insight and a thought-through strategic approach are our tools for delivering solutions that benefit our clients and...

Latest intelligence

UK life sciences minister George Freeman
Creating a 21st century life sciences ecosystem
The UK’s life sciences minister on how government and pharma can encourage NHS uptake and innovation...
Improving Corporate Memory as a Patient Safety Strategy
An article by Lorri Zipperer...
Online Physician Communities
How can pharma innovate in child and TYA cancer?
by Dr Tim Ringrose, M3 (EU)...